Holding shares in Alnylam Pharmaceuticals (ALNY)
isn’t for the weak-hearted, as seen recently in reaction to a
competitor’s unexpectedly strong clinical data. While Alnylam has long
been volatile, and remains risky given the nature of the diseases it
targets and its reliance on biomarker data, it is also close to its
first drug approval and what may well prove to be a multiyear run of
drug approvals that will quickly make the company a player in rare
diseases.
Click here to continue:
Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals
No comments:
Post a Comment